PTPN11 and pulmonary fibrosis: Interestingly, we and others have shown that SHP2 is also a target of nintedanib, an FDA-approved anti-fibrotic compound for the treatment of pulmonary fibrosis that acts as a kinase inhibitor but also as a phosphatase activator [12,27].